All In Biotech

Investigational drug · Phase 2

HRS-7085

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Adult Patients With Moderately to Severely Active Ulcerative Colitis.

Phase 2

Last checked: Nov 20, 2026Latest source record: Jun 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

4

Any phase or sponsor naming "HRS-7085"

First trial start

2025

Oct 17, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "HRS-7085", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Adult Patients With Moderately to Severely Active Ulcerative Colitis

Approved drugs for the same conditions: Ulcerative colitis · Immunology and inflammation

Largest trials

Live from ClinicalTrials.gov: studies naming "HRS-7085" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Adult Patients With Moderately to Severely Active Ulcerative Colitis

  • SHR-1139Phase 25 trials

    Guangdong Hengrui Pharmaceutical Co., Ltd · Moderate to Severe Plaque Psoriasis, Palmoplantar Pustulosis of Adults, Pyoderma Gangrenosum

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.